Duodenal IgE and mast cells changes in diabetes mellitus patients

Abstract

Aims: To determine the differences in duodenal biopsies of diabetes mellitus (DM) patients and non-diabetic patients by investigating the numbers of immunoglobulin E (IgE) positive plasma cells, IgE positive mast cells, and eosinophils. Methods: Patients diagnosed with chronic duodenitis and DM and those diagnosed only with chronic duodenitis within between 2010-2020 years were detected from the hospital information system. Paraffin blocks and hematoxylin-eosin-stained preparations of the patients’ duodenal biopsies were obtained from the hospital’s pathology archive. By performing IgE immunohistochemical staining for all blocks, the sections were evaluated through light microscopy. Results: A total of 75 patients, 45 with DM and 30 non-diabetic patients with chronic duodenitis were included in the study. While IgE accumulation was prominently detected in the plasma cells and mast cells of DM patients’ duodenal tissue samples, no significant IgE accumulation was detected in the biopsies of non-diabetic patients with chronic duodenitis. Conclusion: To date, the effectiveness of mast cells, IgE, and duodenal histological changes in DM have been proven, but our study is the first to detect the increase in mast cells and IgE in duodenal biopsies of DM patients. High IgE in the duodenum could support the relationship between DM and food allergy. We consider that higher IgE antibodies detected in diabetic patients’ duodenums will reveal promising novel results in elucidating DM pathophysiology and regulating the treatment modalities, and will shed light on future studies.

Keywords

• Diabetes mellitus
• Ig E
• mast cells

References

1. Rao JN, Wang JY. Regulation of gastrointestinal mucosal growth. San Rafael (CA): Morgan & Claypool Life Sciences; 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK54091/
2. Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes. 2013;4(3):51-63.
3. Zhong HJ, Yuan Y, Xie WR, Chen MH, He XX. Type 2 diabetes mellitus is associated with more serious small intestinal mucosal injuries. PLoS One. 2016;11(9):e0162354.
4. Zhao M, Liao D, Zhao J. Diabetes-induced mechanophysiological changes in the small intestine and colon. World J Diabetes. 2017;8(6):249-269.
5. Kalaichelvi S. Prevalence of symptomatic peptic ulcer in diabetes mellitus patients at outpatient department of Government Medical College and Hospital in and around Villupuram District. Int Arch Integrated Med. 2018;5(2)111-115.
6. Darra A, Singh V, Jena A, et al. Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment. Scientific Rep. 2023;13(1):11038.
7. Lerkdumnernkit N, Sricharoenvej S, Lanlua P, et al. The effects of early diabetes on duodenal alterations in the rats. Int J Morphol. 2022;40(2)389-395.
8. Maurer M, Taube C, Schröder NWJ, et al. Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. J Allergy Clin Immunol. 2019;144(4S):S19-S30.

9. Hoh RA, Joshi SA, Lee JY, et al. Origins and clonal convergence of gastrointestinal IgE+ B cells in human peanut allergy. Sci Immunol. 2020;5(45):eaay4209.
10. Sun P, Wen H, Liu X, Ma Y, Jang J, Yu C. Time trends in type 2 diabetes mellitus incidence across the BRICS from 1990 to 2019: an age-period-cohort analysis. BMC Public Health. 2022;22(1):65.
11. Lega IC, Lipscombe LL. Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr Rev. 2020;41(1):bnz014.
12. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2016;92(1084):63-69.
13. Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr. 2019;13(1):364-372.
14. Brunkwall L, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia. 2017;60(6):943-951.
15. Frydrych LM, Bian G, O’Lone DE, Ward PA, Delano MJ. Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol. 2018;104(3):525-534.
16. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41(1):36-48.
17. Wang Z, Zhang H, Shen XH, et al. Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans. Ann Med. 2013;45(3):220-229.
18. Wang Z, Zhang H, Shen XH, et al. Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans. Ann Med. 2013;45(3):220-229.
19. Divoux A, Moutel S, Poitou C, et al. Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. J Clin Endocrinol Metab. 2012;97(9):E1677-E1685.
20. Divoux A, Moutel S, Poitou C, et al. Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. J Clin Endocrinol Metab. 2012;97(9):E1677-E1685.
21. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15(8):940-945.
22. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15(8):940-945.
23. Svensson J, Eising S, Mortensen HB, et al. High levels of immunoglobulin E and a continuous increase in immunoglobulin G and immunoglobulin M by age in children with newly diagnosed type 1 diabetes. Hum Immunol. 2012;73(1):17-25.
24. Maier LM, Howson JM, Walker N, et al. Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes. J Allergy Clin Immunol. 2006;117(6):1306-1313.
25. Caffarelli C, Romanini E, Caruana P, Street ME, de’ Angelis G. Clinical food hypersensitivity: the relevance of duodenal immunoglobulin e-positive cells. Pediatr Res. 1998;44(4):485-490.
26. Andre F, Andre C, Descos L, Colin L, Cavagna S. Diagnosis of food allergy by counting IgE-positive duodenal cells. Revue Française D’allergologie et D’immunologie Clinique. 1993;33(2):119-123.
27. Berczi L, Sebestyén A, Fekete B, Tamássy K, Kopper L. IgE-containing cells in gastric mucosa with and without Helicobacter pylori infection. Pathol Res Pract. 2000;196(12):831-834.
28. Concepción Zavaleta MJ, Gonzáles Yovera JG, Moreno Marreros DM, et al. Diabetic gastroenteropathy: an underdiagnosed complication. World J Diabetes. 2021;12(6):794-809.
29. Zopf Y, Baenkler HW, Silbermann A, Hahn EG, Raithel M. The differential diagnosis of food intolerance. Dtsch Arztebl Int. 2009;106(21):359-370.
30. Willis FB, Susan P, Patch A. Prediabetes reduction from food allergen elimination. Med Clin Case Rep. 2023;3(1):1-3.
31. Willis FB, Shanmugam R, Sullivan JH, Rodriguez JP, Mouton CP. Food allergen elimination for obesity reduction; a longitudinal, case-control trial (n= 94): 2295. Med Sci Sports Exercise. 2022;54(9):671.
32. Hessner MJ, Wang X, Meyer L, et al. Involvement of eotaxin, eosinophils, and pancreatic predisposition in development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol. 2004;173(11):6993-7002.